163 related articles for article (PubMed ID: 36833460)
1. Understanding Drug Resistance of Wild-Type and L38HL Insertion Mutant of HIV-1 C Protease to Saquinavir.
Venkatachalam S; Murlidharan N; Krishnan SR; Ramakrishnan C; Setshedi M; Pandian R; Barh D; Tiwari S; Azevedo V; Sayed Y; Gromiha MM
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833460
[TBL] [Abstract][Full Text] [Related]
2. Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potency.
Goldfarb NE; Ohanessian M; Biswas S; McGee TD; Mahon BP; Ostrov DA; Garcia J; Tang Y; McKenna R; Roitberg A; Dunn BM
Biochemistry; 2015 Jan; 54(2):422-33. PubMed ID: 25513833
[TBL] [Abstract][Full Text] [Related]
3. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.
Markland W; Rao BG; Parsons JD; Black J; Zuchowski L; Tisdale M; Tung R
J Virol; 2000 Aug; 74(16):7636-41. PubMed ID: 10906218
[TBL] [Abstract][Full Text] [Related]
4. Revealing the drug resistance mechanism of saquinavir due to G48V and V82F mutations in subtype CRF01_AE HIV-1 protease: molecular dynamics simulation and binding free energy calculations.
C S V; Munusami P
J Biomol Struct Dyn; 2023 Feb; 41(3):1000-1017. PubMed ID: 34919029
[TBL] [Abstract][Full Text] [Related]
5. Drug Resistance Mechanism of M46I-Mutation-Induced Saquinavir Resistance in HIV-1 Protease Using Molecular Dynamics Simulation and Binding Energy Calculation.
Rana N; Singh AK; Shuaib M; Gupta S; Habiballah MM; Alkhanani MF; Haque S; Reshi MS; Kumar S
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458427
[TBL] [Abstract][Full Text] [Related]
6. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
7. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
[TBL] [Abstract][Full Text] [Related]
8. Insights into the mechanism of drug resistance: X-ray structure analysis of G48V/C95F tethered HIV-1 protease dimer/saquinavir complex.
Prashar V; Bihani SC; Das A; Rao DR; Hosur MV
Biochem Biophys Res Commun; 2010 Jun; 396(4):1018-23. PubMed ID: 20471372
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
Prashar V; Bihani SC; Ferrer JL; Hosur MV
Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
[TBL] [Abstract][Full Text] [Related]
10. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
Liu F; Kovalevsky AY; Tie Y; Ghosh AK; Harrison RW; Weber IT
J Mol Biol; 2008 Aug; 381(1):102-15. PubMed ID: 18597780
[TBL] [Abstract][Full Text] [Related]
11. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
Tzoupis H; Leonis G; Avramopoulos A; Mavromoustakos T; Papadopoulos MG
J Phys Chem B; 2014 Aug; 118(32):9538-52. PubMed ID: 25036111
[TBL] [Abstract][Full Text] [Related]
12. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
Valer L; de Mendoza C; Soriano V
J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
Hong L; Zhang XC; Hartsuck JA; Tang J
Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of drug resistance in HIV-1 protease subtype C in the presence of Atazanavir.
Sankaran SV; Krishnan SR; Sayed Y; Gromiha MM
Curr Res Struct Biol; 2024; 7():100132. PubMed ID: 38435053
[TBL] [Abstract][Full Text] [Related]
16. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Schapiro JM; Winters MA; Lawrence J; Merigan TC
AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
[TBL] [Abstract][Full Text] [Related]
17. Insight into analysis of interactions of saquinavir with HIV-1 protease in comparison between the wild-type and G48V and G48V/L90M mutants based on QM and QM/MM calculations.
Saen-oon S; Aruksakunwong O; Wittayanarakul K; Sompornpisut P; Hannongbua S
J Mol Graph Model; 2007 Nov; 26(4):720-7. PubMed ID: 17543558
[TBL] [Abstract][Full Text] [Related]
18. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
19. The impact of active site mutations of South African HIV PR on drug resistance: Insight from molecular dynamics simulations, binding free energy and per-residue footprints.
Ahmed SM; Maguire GE; Kruger HG; Govender T
Chem Biol Drug Des; 2014 Apr; 83(4):472-81. PubMed ID: 24267738
[TBL] [Abstract][Full Text] [Related]
20. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
Velazquez-Campoy A; Vega S; Freire E
Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]